Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy: are we making a difference?

J P Dutcher1

  • 1New York Medical College and Our Lady of Mercy Cancer Centre, Bronx 10466, USA. jpd4401@aol.com

Current Opinion in Urology
|September 27, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM<sup>SM</sup> registry.

Journal for immunotherapy of cancer·2019
Same author

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Characterization of bone metastases in patients with renal cell cancer.

BJU international·2004
Same author

Accelerated and blastic phase of chronic myeloid leukemia.

Current treatment options in oncology·2002
Same author

Phase I study of recombinant human CD40 ligand in cancer patients.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

Angiogenesis and melanoma.

Current oncology reports·2001
Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026
Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026
Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026
Same journal

Shaping the future of endourology: role of education, simulation and uro-technology: a scoping review by the EAU Section of Endourology.

Current opinion in urology·2026
Same journal

A review of emerging technologies and techniques for percutaneous nephrolithotomy access.

Current opinion in urology·2026
Same journal

Artificial intelligence in kidney cancer: a review of clinical applications across the disease spectrum.

Current opinion in urology·2026
See all related articles

Immunotherapy for metastatic renal cell cancer shows anti-tumour effects in some patients. Ongoing research focuses on new immune activation technologies to improve response rates and outcomes.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immunotherapy has a 10-20 year history in treating metastatic renal cell cancer.
  • Current immunotherapeutic agents demonstrate anti-tumour effects in a subset of patients.
  • Dosing and scheduling of existing treatments are continually refined.

Purpose of the Study:

  • To explore advancements in immunotherapeutic approaches for metastatic renal cell cancer.
  • To investigate new technologies for enhancing immune system activation.
  • To improve response rates and patient outcomes in renal cell cancer treatment.

Main Methods:

  • Review of historical and current immunotherapeutic strategies.
  • Analysis of emerging immune system activation technologies.
  • Evaluation of anti-proliferative effects and stable disease prolongation.

Related Experiment Videos

Main Results:

  • Consistent demonstration of anti-tumour activity in a small patient percentage.
  • Ongoing modification of dose and schedule for current agents.
  • Development of new agents to enhance therapeutic approaches.

Conclusions:

  • Immunotherapy offers a demonstrated, albeit limited, anti-tumour effect in metastatic renal cell cancer.
  • Further research into novel immune activation technologies is crucial.
  • New agents are being developed to enhance the anti-proliferative and disease-stabilizing effects of immunotherapy.